A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors

Trial Profile

A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 19 Jan 2018

At a glance

  • Drugs Everolimus (Primary) ; Lenvatinib (Primary)
  • Indications CNS cancer; Ewing's sarcoma; Glioma; Neuroectodermal tumours; Rhabdomyosarcoma; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Eisai Inc
  • Most Recent Events

    • 04 Jan 2018 Planned primary completion date changed from 31 Mar 2022 to 30 Jun 2022.
    • 04 Jan 2018 Status changed from not yet recruiting to recruiting.
    • 14 Aug 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top